Novel Strategies in the Thiopurine Treatment of Inflammatory Bowel Disease

REFERENCES

• Lindqvist , M. , Hindorf , U. , Almer , S. and Peterson , C. 2006 . Thiopurines in inflammatory bowel disease–the role of pharmacogenetics and therapeutic drug monitoring . Current Pharmacogenomics , 4 : 285 – 300 .
   Google Scholar
• Prefontaine , E. , Sutherland , L. R. , Macdonald , J. K. and Cepoiu , M. 2009 . Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease . Cochrane Database Syst. Rev. , Jan 21 ( 1 ) : CD000067
   Google Scholar
• Markowitz , J. , Grancher , K. , Kohn , N. , Lesser , M. and Daum , F. 2000 . A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease . Gastroenterology , 119 : 895 – 902 .
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet , L. , Deltenre , P. , Ardizzone , S. , D’Haens , G. , Hanauer , S. B. , Herfarth , H. , Lémann , M. and Colombel , J. F. 2009 . Azathioprine and 6-Mercaptopurine for the prevention of postoperative recurrence in Crohn's Disease: A meta-analysis . Am. J. Gastroenterol. , 104 : 2089 – 2096 .
   PubMed Web of Science ®Google Scholar
• Hawthorne , A. B. , Logan , R. F. , Hawkey , C. J. , Foster , P. N. , Axon , A. T. , Swarbrick , E. T. , Scott , B. B. and Lennard-Jones , J. E. 1992 . Randomised controlled trial of azathioprine withdrawal in ulcerative colitis . BMJ , 305 : 20 – 22 .
   PubMed Web of Science ®Google Scholar
• Ardizzone , S. , Maconi , G. , Russo , A. , Imbesi , V. , Colombo , E. and Bianchi Porro , G. 2006 . Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis . Gut , 55 : 47 – 53 .
   PubMed Web of Science ®Google Scholar
• Hindorf , U. , Lindqvist , M. , Hildebrand , H. , Fagerberg , U. and Almer , S. 2006 . Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease . Aliment Pharmacol. Ther. , 24 : 331 – 342 .
   PubMed Web of Science ®Google Scholar
• Hindorf , U. , Johansson , M. , Eriksson , A. , Kvifors , E. and Almer , S. H. 2009 . Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease . Aliment Pharmacol. Ther. , 29 : 654 – 661 .
   PubMed Web of Science ®Google Scholar
• Almer , S. H. , Hjortswang , H. and Hindorf , U. 2009 . 6-Thioguanine therapy in Crohn's disease–observational data in Swedish patients . Dig. Liver Dis. , 41 : 194 – 200 .
   PubMedGoogle Scholar
• Teml , A. , Schwab , M. , Hommes , D. W. , Almer , S. , Lukas , M. , Feichtenschlager , T. , Florin , T. , Seiderer , J. , Petritsch , W. , Bokemeyer , B. , Kreisel , W. , Herrlinger , K. R. , Knoflach , P. , Bonaz , B. , Klugmann , T. , Herfarth , H. , Pedarnig , N. and Reinisch , W. 2007 . A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease . Wien. Klin. Wochenschr. , 119 : 519 – 526 .
   PubMed Web of Science ®Google Scholar
• de Boer , N. K. , Zondervan , P. E. , Gilissen , L. P. , den Hartog , G. , Westerveld , B. D. , Derijks , L. J. , Bloemena , E. , Engels , L. G. , van Bodegraven , A. A. and Mulder , C. J. 2008 . Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients . Dig. Liver Dis. , 40 : 108 – 113 .
   PubMedGoogle Scholar
• Lémann , M. , Mary , J. Y. , Duclos , B. , Veyrac , M. , Dupas , J. L. , Delchier , J. C. , Laharie , D. , Moreau , J. , Cadiot , G. , Picon , L. , Bourreille , A. , Sobahni , I. and Colombel , J. F. 2006 . Groupe d’Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial . Gastroenterology , 130 : 1054 – 1061 .
   PubMed Web of Science ®Google Scholar
• Sandborn , W. J. , Rutgeerts , P. J. , Reinisch , W. , Mantzaris , G. J. , Kornbluth , A. , Rachmilewitz , D. , Lichtiger , S. , D’Haens , G. R. , van der Woude , C. J. , Diamond , R. , Broussard , D. , Tang , K. L. and Colombel , J. F. 2009 . One year data from the Sonic Study: A randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy . Gastroenterology , 136 ( Suppl 1 ) : 751f
   Google Scholar
• de Boer , N. K. , Derijks , L. J. , Keizer-Garritsen , J. J. , Lambooy , L. H. , Ruitenbeek , W. , Hooymans , P. M. , van Bodegraven , A. A. and de Jong , D. J. 2007 . Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease . J. Clin. Pharmacol. , 47 : 187 – 191 .
   PubMed Web of Science ®Google Scholar
• Vikingsson , S. , Carlsson , B. , Almer , S. H. and Peterson , C. 2009 . Monitoring of thiopurine metabolites in patients with inflammatory bowel disease-what is actually measured? . Ther. Drug Monit. , 31 : 345 – 350 .
   PubMed Web of Science ®Google Scholar
• Neurath , M. F. , Kiesslich , R. , Teichgräber , U. , Fischer , C. , Hofmann , U. , Eichelbaum , M. , Galle , P. R. and Schwab , M. 2005 . 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease . Clin. Gastroenterol. Hepatol. , 3 : 1007 – 1014 .
   PubMed Web of Science ®Google Scholar
• Tiede , I. , Fritz , G. , Strand , S. , Poppe , D. , Dvorsky , R. , Strand , D. , Lehr , H. A. , Wirtz , S. , Becker , C. , Atreya , R. , Mudter , J. , Hildner , K. , Bartsch , B. , Holtmann , M. , Blumberg , R. , Walczak , H. , Iven , H. , Galle , P. R. , Ahmadian , M. R. and Neurath , M. F. 2003 . CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes . J. Clin. Invest. , 111 : 1133 – 1145 .
   PubMed Web of Science ®Google Scholar
• Dubinsky , M. C. , Lamothe , S. , Yang , H. Y. , Targan , S. R. , Sinnett , D. , Théorêt , Y. and Seidman , E. G. 2000 . Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease . Gastroenterology , 118 : 705 – 713 .
   PubMed Web of Science ®Google Scholar
• Hindorf , U. , Lyrenäs , E. , Nilsson , A. and Schmiegelow , K. 2004 . Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease . Scand. J. Gastroenterol. , 39 : 1105 – 1112 .
   PubMed Web of Science ®Google Scholar
• Osterman , M. T. , Kundu , R. , Lichtenstein , G. R. and Lewis , J. D. 2006 . Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis . Gastroenterology , 130 : 1047 – 1053 .
   PubMed Web of Science ®Google Scholar
• de Boer , N. K. , Wong , D. R. , Jharap , B. , de Graaf , P. , Hooymans , P. M. , Mulder , C. J. , Rijmen , F. , Engels , L. G. and van Bodegraven , A. A. 2007 . Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism . Am. J. Gastroenterol. , 102 : 2747 – 2753 .
   PubMed Web of Science ®Google Scholar
• Hindorf , U. , Lindqvist , M. , Peterson , C. , Söderkvist , P. , Ström , M. , Hjortswang , H. , Pousette , A. and Almer , S. 2006 . Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease . Gut. , 55 : 1423 – 1431 .
   PubMed Web of Science ®Google Scholar
• Dubinsky , M. C. , Yang , H. , Hassard , P. V. , Seidman , E. G. , Kam , L. Y. , Abreu , M. T. , Targan , S. R. and Vasiliauskas , E. A. 2002 . 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease . Gastroenterology , 122 : 904 – 915 .
   PubMed Web of Science ®Google Scholar
• Sparrow , M. P. , Hande , S. A. , Friedman , S. , Cao , D. and Hanauer , S. B. 2007 . Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine . Clin. Gastroenterol. Hepatol. , 5 : 209 – 214 .
   PubMed Web of Science ®Google Scholar
• Schaeffeler , E. , Fischer , C. , Brockmeier , D. , Wernet , D. , Moerike , K. , Eichelbaum , M. , Zanger , U. M. and Schwab , M. 2004 . Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants . Pharmacogenetics , 14 : 407 – 417 .
   PubMedGoogle Scholar
• Haglund , S. , Taipalensuu , J. , Peterson , C. and Almer , S. 2008 . IMPDH activity in thiopurine-treated patients with inflammatory bowel disease-relation to TPMT activity and metabolite concentrations . Br. J. Clin. Pharmacol. , 65 : 69 – 77 .
   PubMed Web of Science ®Google Scholar
• Haglund , S. , Vikingsson , S. , Taipalensuu , J. , Coulthard , S. , Hindorf , H. , Danelius , M. , Peterson , C. and Almer , S. H. 2009 . A “Skewed” thiopurine metabolite profile in IBD patients is not explained by variations in inosine-5-monophosphate dehydrogenase activity . Gastroenterology , 136 ( Suppl 1 ) : W1208
   Google Scholar
• Sparrow , M. P. , Hande , S. A. , Friedman , S. , Lim , W. C. , Reddy , S. I. , Cao , D. and Hanauer , S. B. 2005 . Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine . Aliment Pharmacol. Ther. , 22 : 441 – 446 .
   PubMed Web of Science ®Google Scholar